Last edited by Mazusho
Monday, February 10, 2020 | History

2 edition of Tumor-associated antigens and their specific immune response found in the catalog.

Tumor-associated antigens and their specific immune response

Tumor-associated antigens and their specific immune response

  • 214 Want to read
  • 34 Currently reading

Published by Academic Press in London, New York .
Written in English

    Subjects:
  • Tumor antigens -- Congresses.,
  • Tumors -- Immunological aspects -- Congresses.,
  • Immune response -- Congresses.,
  • Immunotherapy -- Congresses.

  • Edition Notes

    Includes bibliographies and index.

    Statementedited by F. Spreafico, R. Arnon.
    SeriesProceedings of the Serono Symposia ;, v. 16
    ContributionsSpreafico, Federico., Arnon, R.
    Classifications
    LC ClassificationsQR188.6 .T85
    The Physical Object
    Paginationviii, 359 p. :
    Number of Pages359
    ID Numbers
    Open LibraryOL4748521M
    ISBN 100126583501
    LC Control Number78067900

    Two types of tumor antigens have been identified on tumor cells: tumor-specific transplantation antigens TSTAs and tumor-associated transplantation antigens TATAs. T cells cannot bind native antigens, but require that they be processed by APCs, whereas B cells can be activated by native ones. Tumorigenesis may lead to expression of new antigens neoantigens or alteration in existing antigens that are found on normal cells. Evidence for immune reactivity to tumors There is a lot of evidence that tumors can elicit an immune response. These antigens may include membrane receptors, regulators of cell cycle and apoptosis, or molecules involved in signal transduction pathways.

    Cancer Immunology, Immunotherapy, Both active and passive means of stimulating the non-specific and specific immune systems have been employed, in some cases with significant success. Details of glycan binding by FG88 mAbs. Overexpression of SLex and SLea appears to directly correlate with increased metastatic disease and poorer overall survival in patients with colorectal cancer invasion [ 73 ].

    Sialic acids on normal cells are involved in multiple different physiologic processes [ 44 ]. The mAb recognises dimeric Lea epitope and cross reacts with simple Lea and extended Lea epitopes. Further glycosylation steps are catalysed by different glycosyltransferases with different specificities and result in the generation of more complex GSLs [ 16 ]. Of these glycolipids, GSLs are the ones that are most widely overexpressed on tumours [ 10 ]. Our vaccine also provides an opportunity to combine this approach with another immune therapy approach, checkpoint inhibitors, to maximize possible immune therapy impact on specific cancers.


Share this book
You might also like
Refugees into higher education

Refugees into higher education

Abstracts of lectures, symposia, and free communications

Abstracts of lectures, symposia, and free communications

Sedition

Sedition

Technique of ballroom dancing

Technique of ballroom dancing

Total quality management and organisational change

Total quality management and organisational change

handbook for candidates for election to the House of the People and legislative assemblies.

handbook for candidates for election to the House of the People and legislative assemblies.

Operating problems of California corporations

Operating problems of California corporations

1 John (Geneva)

1 John (Geneva)

Halloween

Halloween

Little critters

Little critters

Year presents a picture history of the bible and christianityin 1000 pictures

Year presents a picture history of the bible and christianityin 1000 pictures

bar reviewer on the power of taxation

bar reviewer on the power of taxation

Discussion Document

Discussion Document

Tumor-associated antigens and their specific immune response book

This approach was successfully used to identify a large number of antigenic peptides [ 1315 — 17 ]. The expression of these cancer-associated antigens results mainly from the upregulation of sialyltransferases [ 68 ]. In order to keep the cytotoxic cells from killing cells just for presenting self-proteins, the cytotoxic cells self-reactive T cells are deleted as a result of tolerance negative selection.

A third approach to antigen identification is based on the elution of antigenic peptides from MHC class I molecules immunopurified from the surface of tumor cells [ 21 — 24 ].

Common glycoconjugates on human cells. This observation demonstrated that MHC class I molecules continuously display on the cell surface peptides of 8 to 10 amino acids that are derived from a wide variety of, if not all, intracellular proteins [ 9 ].

Since tumors can mutate rapidly, we believe timely and specific immunostimulation is critical. Tumor antigen Tumor in which it is found Remarks.

Monoclonal Antibodies Against Tumour

Mutation of protooncogenes and tumor suppressors which lead to abnormal protein production are the cause of the tumor and thus such abnormal proteins are called tumor-specific antigens. Altered ganglioside expression Gangliosides are acidic glycosphingolipids with the presence of at least one sialic acid linked to their oligosaccharide chain [ 75 ].

In addition, certain tumors are known to lack or be poor expressers of MHC antigen. Immunization experiments in mice were promising, with activity depending as it should on the number of responsive T-cells.

Specific Killed tumor cells or their extract, recombinant antigens, idiotype, co-stimulatory molecule genes, etc. Immuno-diagnosis Monoclonal antibodies labeled with radioisotope have been used for in vivo detection of relatively small tumor foci. They used medullary thymic epithelial cells, which have a huge transcriptome already, as the controls: chopping the RNA-seq reads into base pieces and getting rid of everything that showed up in those normal cells leaves a residue of potential TSAs, coding regions or not.

Some antigens start out as exogenous, and later become endogenous for example, intracellular viruses. Cytokines such as IFN-gamma may also activate macrophages to be tumoricidal. Details of glycan binding by FG88 mAbs. Sialic acid-binding immunoglobulin-like lectins Siglecs are receptor families that specifically recognise sialoglycans.

Thus, the Th cells provide help to B cells in antibody production. In general, sialic acids terminate the outer end of glycans sialoglycans via more than 20 distinct Golgi-resident sialyltransferases ST. However, due to impaired immune reactivity, cancer cells may escape destruction.Jun 16,  · Most peptide/MHC complexes displayed at the surface of healthy cells are not recognized by T cells as a result of self-tolerance.

Human Tumor Antigens and Cancer Immunotherapy

However, in tumor cells or cells infected by a virus, a new repertoire of peptides is produced, which is derived from viral or tumor-associated proteins and against which an immune response can be atlasbowling.com by: tumor-specific antigen: [ an´tĭ-jen ] any substance capable, under appropriate conditions, of inducing a specific immune response and reacting with the products of that response; that is, with specific antibody or specifically sensitized T lymphocytes, or both.

Antigens may be soluble substances, such as toxins and foreign proteins, or. May 01,  · The question of whether human tumors express antigens that can be recognized by the immune system has been answered with a resounding YES. Most were identified through spontaneous antitumor humoral and cellular immune responses found in cancer patients and include peptides, glycopeptides, phosphopeptides, viral peptides, and peptides resulting from common mutations in Cited by: In response to IFN-g, this subunit composition is changed, leading to the Subclasses of Tumor-associated T-cell Antigens categorized by their expression pattern as unique antigens, cancer testis antigens, differentiation antigens, and overexpressed antigens.

Download PDF: Sorry, we are unable to provide the full text but you may find it at the following location(s): atlasbowling.comg (external link)Author: B.

M. Vose. Oct 17,  · The more tumor-associated antigens presented, the greater likelihood of a successful immune response.

Tumor Antigens

The initial research on this approach was conducted in rodent models using prostate, ovarian and melanoma tumors. This response was further improved by the addition of a novel adjuvant designed to enhance the cellular immune atlasbowling.com: Mark Suckow, DVM.